Prospective randomized comparisons of ranitidine bismuth citrate (RBC) versus colloidal bismuth subcitrate (Denol)-based triple therapy for the treatment of H-pylori infection.

被引：0
|
作者：
Kung, NNS
Sung, JY
Yuen, WF
Li, TH
Ng, PW
Lai, WM
Leung, MF
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Hong Kong
[2] United Christian Hosp, Dept Med, Hong Kong, Hong Kong
[3] United Christian Hosp, Dept Pathol, Hong Kong, Hong Kong
[4] United Christian Hosp, Dept Microbiol, Hong Kong, Hong Kong
来源：
GASTROENTEROLOGY | 1998年 / 114卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(98)80774-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
G0780
引用
收藏
页码：A190 / A190
页数：1
相关论文
共 50 条
  • [31] Ranitidine bismuth citrate-based versus Levofloxacin-based triple rescue therapy after Helicobacter pylori treatment failure
    Gisbert, J. P.
    Gisbert, J. L.
    Marcos, S.
    Moreno-Otero, R.
    Pajares, J. M.
    HELICOBACTER, 2006, 11 (04) : 386 - 386
  • [32] One-week therapy with omeprazole or ranitidine bismuth citrate plus clarithromycin and and amoxicillin for treatment of Helicobacter pylori infection.
    Rojas, M
    Hergueta, P
    Romero, R
    Gomez, BJ
    Pellicer, FJ
    Herrerias, JM
    GASTROENTEROLOGY, 2000, 118 (04) : A1300 - A1300
  • [33] Ranitidine bismuth citrate (RBC) plus amoxycillin and tinidazole as second-line therapy for H.pylori infection after failure of the standard "Maastricht triple therapy"
    Perri, F
    Villani, MR
    Annese, V
    Quitadamo, M
    Niro, GA
    Mangia, A
    Andriulli, A
    GASTROENTEROLOGY, 2001, 120 (05) : A581 - A581
  • [34] One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese
    Hung, WK
    Wong, WM
    Wong, GSW
    Yip, AWC
    Szeto, ML
    Lai, KC
    Hu, WHC
    Chan, CK
    Xia, HHX
    Yuen, MF
    Fung, FMY
    Tong, TSM
    Ho, VYK
    Lam, SK
    Wong, BCY
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (12) : 2067 - 2072
  • [35] Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer
    Catalano, F
    Catanzaro, R
    Bentivegna, C
    Brogna, A
    Condorelli, G
    Cipolla, R
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1998, 12 (01) : 59 - 62
  • [36] The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection
    Van der Wouden, EJ
    Thijs, JC
    Van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (03) : 297 - 302
  • [37] Quadruple therapy using esomeprazole, furazolidone, amoxicillin-clavulanate, and colloidal bismuth subcitrate in patients who failed to eradicate H-pylori with triple therapy
    Abbas, Zaigham
    Yakoob, Javed
    Abid, Shahab
    Jafri, Wasim
    GASTROENTEROLOGY, 2007, 132 (04) : A614 - A614
  • [38] Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection
    Cestari, R
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1998, 12 (10) : 991 - 996
  • [39] Ranitidine bismuth citrate (RBC) is more effective than omeprazole in the eradication of H-pylori when co-prescribed with clarithromycin
    Pare, P
    Romaozinho, J
    Bardhan, KD
    French, PC
    Roberts, PM
    GASTROENTEROLOGY, 1997, 112 (04) : A251 - A251
  • [40] A multicenter randomized trial with twice daily ranitidine bismuth-citrate (R), metronidazole (M) and tetracycline (T) for 7 or 10 days for eradication of H-pylori infection.
    Knigge, K
    Kelly, C
    Fennerty, MB
    Peterson, WL
    GASTROENTEROLOGY, 1998, 114 (04) : A180 - A180
12345